Erythema Toxicum Neonatorum in Newborns and the Development of Asthma

This study has been completed.
Sponsor:
Information provided by:
University of Rochester
ClinicalTrials.gov Identifier:
NCT00178152
First received: September 12, 2005
Last updated: May 11, 2011
Last verified: May 2011
  Purpose

Erythema Toxicum Neonatorum (ETN) is a common skin finding that affects healthy full-term babies. Several authors have commented on the possible relationship between ETN and the development of atopic conditions, such as atopic dermatitis or respiratory disease later in life. There is a paucity of research addressing this issue.


Condition
Asthma
Erythema Toxicum Neonatorum

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: The Implication of Erythema Toxicum Neonatorum in Newborns on the Development of Future Asthma

Resource links provided by NLM:


Further study details as provided by University of Rochester:

Enrollment: 334
Study Start Date: May 2005
Study Completion Date: November 2005
Primary Completion Date: November 2005 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   3 Years to 9 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Case studies will include subjects between the ages of 3-9 years who have had at least 2 asthma diagnoses within the last 2 years. Patients will be selected based upon their ICD9 codes for asthma. Control subjects will be age matched and without an asthma diagnosis.

Criteria

Inclusion Criteria:

  • Children between the ages of 3-9 years who have had at least 2 asthma diagnoses within the last 2 years.
  • Control subjects will be age matched and without an asthma diagnosis.

Exclusion Criteria:

  • Children without accessible medical records
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00178152

Locations
United States, New York
Department of Pediatrics, University of Rochester
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
Investigators
Principal Investigator: Jill S Halterman, MD, MPH University of Rochester
Study Chair: Ritu Pabby, MD West Penn Allegheny Health System
  More Information

No publications provided

Responsible Party: Jill S. Halterman, MD, MPH, University of Rochester
ClinicalTrials.gov Identifier: NCT00178152     History of Changes
Other Study ID Numbers: 11627
Study First Received: September 12, 2005
Last Updated: May 11, 2011
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Asthma
Erythema
Bronchial Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases
Skin Diseases

ClinicalTrials.gov processed this record on October 23, 2014